The Global and Regional Challenge of Pan-Antibiotic Resistance: A Review of Emerging Threats and Mechanisms

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 02 | Page :
    By

    Sharique Ahmad,

  • Dilshad Ali Rizvi,

  • Md Shumayel Athar Khan,

  • Subuhi Anwar,

  • Ruvy Verma,

  • Mayuri Agarwal,

  1. Professor, Department of Pathology, Era’s Lucknow Medical College and Hospital, Era University, Safarazganj, Hardoi road, Lucknow, Uttar Pradesh, India
  2. Professor, Department of Pharmacology, Era’s Lucknow Medical College and Hospital, Era University, Safarazganj, Hardoi road, Lucknow, Uttar Pradesh, India
  3. MBBS Intern, Laxmi Chandravanshi Medical College & Hospital, Bishrampur, kosiar, Jharkhand, India
  4. Research Assistant, Era’s Lucknow Medical College and Hospital, Era University, Safarazganj, Hardoi road, Lucknow, Uttar Pradesh, India
  5. Junior Resident, Department of Pathology, Era’s Lucknow Medical College and Hospital, Era University, Safarazganj, Hardoi road, Lucknow, Uttar Pradesh, India
  6. Junior Resident, Department of Pathology, Era’s Lucknow Medical College and Hospital, Era University, Safarazganj, Hardoi road, Lucknow, Uttar Pradesh, India

Abstract

Antimicrobial resistance (AMR) is one of the major and most intricate threats to the health of the 21st century as it is core to the undermined expertise of the common clinical practice and public health security worldwide. The problem is characterized by the extensive development of bacterial pathogens into extremely drug-resistant (XDR) and pan-drug-resistant (PDR) so- called superbugs faster than it can be done with therapeutics. It is a synthesis of molecular processes that drive this resistance and the critical issues are critically looked at on the global level and a focal lens on the unique and increased burden in India. We explore the effectiveness and shortcomings of the existing interventions such as antimicrobial stewardship and alternative therapies to contextualize a needed direction into the future of continuing the use of the existing antibiotics and encouraging new one development.

Keywords: antimicrobial resistance, multidrug-resistant, pathogens, therapies, antibiotics

How to cite this article:
Sharique Ahmad, Dilshad Ali Rizvi, Md Shumayel Athar Khan, Subuhi Anwar, Ruvy Verma, Mayuri Agarwal. The Global and Regional Challenge of Pan-Antibiotic Resistance: A Review of Emerging Threats and Mechanisms. International Journal of Antibiotics. 2026; 03(02):-.
How to cite this URL:
Sharique Ahmad, Dilshad Ali Rizvi, Md Shumayel Athar Khan, Subuhi Anwar, Ruvy Verma, Mayuri Agarwal. The Global and Regional Challenge of Pan-Antibiotic Resistance: A Review of Emerging Threats and Mechanisms. International Journal of Antibiotics. 2026; 03(02):-. Available from: https://journals.stmjournals.com/ijab/article=2026/view=248513


References

1. Gaynes R. The discovery of penicillin—new insights after more than 75 years of clinical use. Emerging infectious diseases. 2017 May;23(5):849.
2. Maskalyk J. Antimicrobial resistance takes another step forward. Cmaj. 2002 Aug 20;167(4):375-.
3. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet. 2022 Feb 12;399(10325):629-55.
4. Mudenda S, Chabalenge B, Daka V, Mfune RL, Salachi KI, Mohamed S, Mufwambi W, Kasanga M, Matafwali SK. Global strategies to combat antimicrobial resistance: a one health perspective. Pharmacology & Pharmacy. 2023 Jan 1;14(08):271-328.
5. Kumar M, Babaei P, Ji B, Nielsen J. Human gut microbiota and healthy aging: Recent developments and future prospective. Nutrition and Healthy aging. 2016 Oct 27;4(1):3-16.
6. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. The American journal of medicine. 2006 Jun 1;119(6):S3-10.
7. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrobial agents and chemotherapy. 2010 Mar;54(3):969-76.
8. Berglund F, Marathe NP, Österlund T, Bengtsson-Palme J, Kotsakis S, Flach CF, Larsson DJ, Kristiansson E. Identification of 76 novel B1 metallo-β-lactamases through large- scale screening of genomic and metagenomic data. Microbiome. 2017 Oct 12;5(1):134.
9. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.
10. Fernandes R, Amador P, Prudêncio C. β-Lactams: chemical structure, mode of action and mechanisms of resistance. Reviews and Research in Medical Microbiology. 2013 Jan 1;24(1):7-17.
11. De Lencastre H, Tomasz A. Mechanisms of $beta$-lactam resistance in Staphylococcus aureus. Microb Drug Resist. 1994;1(1):15–26.

12. Arthur M, Quintiliani R Jr. The emergence of vancomycin resistance in enterococci and the theoretical risk of transfer to Staphylococcus aureus. Emerg Infect Dis.
2001;7(2):288–91.
13. Li X-Z, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337–418.
14. Piddock LJV. Clinically relevant changes in efflux pump expression in bacteria. J Antimicrob Chemother. 2006;58(4):758–61.
15. Piddock LJV. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20–51.
16. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593–656.
17. Hancock RE. Mechanisms of uptake and penetration of antibiotics in Gram-negative bacteria. Am J Med. 1986;80(6B):10–6.
18. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer. J Glob Antimicrob Resist. 2008;1(1):1–8.
19. Davison J. Genetic exchange between bacteria in the environment. Plasmid. 1999;42(2):73–91.
20. Toleman MA, Reuter S, Walsh TR. Molecular epidemiology of the plasmid-mediated carbapenemase NDM-1. FEMS Microbiol Rev. 22011;35(3):559–69.
21. Håvarstein LS. Molecular mechanisms of transformation in Streptococcus pneumoniae. J Mol Microbiol Biotechnol. 1999;1(3):329–35.
22. Skurnik M, Pajunen M, Kiljunen S. The last frontier: bacteriophages of Yersinia. Bacteriophage. 2012;2(3):138–48.
23. Aslam B, Khurshid M, Arshad MI, Muzammil S, Rasool M, Yasmeen N, Shah T, Chaudhry TH, Rasool MH, Shahid A, Xueshan X. Antibiotic resistance: one health one world outlook. Frontiers in cellular and infection microbiology. 2021 Nov 25;11:771510.
24. Ajulo S, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PloS one. 2024 Feb 5;19(2):e0297921.
25. Laxminarayan R, Dusek A, Eilbert WP, Eilbert W. The economic costs of antimicrobial resistance: a review of the literature. Infect Control Hosp Epidemiol.
2018;39(12):1428–36.
26. Collignon PJ, Ayling RD. Injudicious use of antibiotics in animals and its impact on human risk. Microbiol Spectr. 2014;2(4):2.4.03.
27. Laxminarayan R. Antibiotic resistance: the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.
28. Mestrovic T, Naghavi M, Aguilar GR, Weaver ND, Swetschinski LR, Wool EE, Araki DT, Hayoon AG, Han C, Ikuta KS, Rosenblad E. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050. The Lancet Public Health. 2025 Nov 1;10(11):e955-70.

29. Kotwani A, Wattal C, Katewa S, Joshi PC, Holloway K. Antibiotic prescribing practices and antibiotic resistance in New Delhi, India. J Antimicrob Chemother.
2010;65(3):557–63.
30. Kotwani A, Wattal C, Joshi PC. Antibiotic resistance in India: a major public health concern. Indian J Med Res. 2012;135(6):799–805.
31. Siddalingaiah HS. Resistance gene patterns and reserve-agent susceptibility in Indian clinical isolates: A One Health analysis of ICMR-AMRSN surveillance data, 2017-2024. One Health Bulletin. 2026:10-4103.
32. Chandra P, Mk U, Ke V, Mukhopadhyay C, U DA, M SR, V R. Antimicrobial resistance and the post antibiotic era: better late than never effort. Expert opinion on drug safety. 2021 Nov 2;20(11):1375-90.
33. Larsson DGJ, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20(5):257–69.
34. Bengtsson-Palme J, Larsson DGJ. The environmental resistome: how does it shape the clinical challenge? J Antimicrob Chemother. 2016;71(12):3327–32.
35. Dyar OJ, Beović B, Pulcini C. Towards a better future for antibiotics: a global strategy. J Antimicrob Chemother. 22017;72(1):1–4.
36. Barlam TF, Cosgrove SE, Abbo LA, MacDougall K, Schuetz MA, Srinivasan A, et al. Implementing antimicrobial stewardship programs in hospitals. Clin Infect Dis.
22016;62(5):e51–77.
37. Dellinger EP, Hausmann B, Johnson E, Cizman B, Krobot-Coumou A. Impact of an antimicrobial stewardship program on antibiotic prescribing and bacterial resistance in a tertiary care center. Surg Infect. 2016;17(3):345–51.
38. Drawz SM, Bonomo RA. Three decades of $beta$-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
39. Dagan R, Baughman W, Givon-Lavi N, Nadir E, Fraser D, Malley R. Secondary Prevention of Invasive Pneumococcal Disease in Children by the 7-Valent Pneumococcal Conjugate Vaccine. Pediatrics. 22005;115(4):893–9.
40. Nkuba EN, Dyar OJ, Sifuna P, Mwangosi H. Challenges in implementing an Antimicrobial Stewardship Program (ASP) in developing countries. PMC.
22025;11722715.
41. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 22011;86(11):1113–23.
42. Nkuba EN, Dyar OJ, Mwangosi H, Marwa G, Stålsby Lundborg C, Sifuna P. Antimicrobial stewardship in low- and middle-income countries: developing a broader
perspective through an ethical analysis. Indian J Med Ethics. 2023;5(4):242–51.
43. Tamma PD, Aitken SL, Barlam TF. Implementing antimicrobial stewardship in the setting of rising antimicrobial resistance. JAMA. 2022;327(20):2020–1.
44. Weterings V, Leijen-Tenk J, van den Briel V, Frijlink HW, Kootstra K, Alffenaar JC. Point-of-care testing in antimicrobial stewardship. Clin Microbiol Infect.
22021;27(1):31–5.
45. Friedman J, Blower S. The benefits of novel drugs and drug combinations in the face of antibiotic resistance. Front Microbiol. 2016;7:1742.

46. Skurnik M, Pajunen M, Kiljunen S. Bacteriophage therapy: a successful alternative to antibiotics. J Virol. 2012;86(14):7187–96.
47. Dąbrowska K, Miedzybrodzki R, Górski A. Bacteriophage therapy for treatment of antibiotic-resistant infections. J Appl Microbiol. 2015;118(1):1–10.
48. Zasloff M. Antimicrobial peptides: potential novel therapeutics. Nat Rev Microbiol. 2002;1(4):226–37.
49. Morones-Ramírez JR, Garza-Cárdenas CR, Garza-Cervantes JA. The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. Front Bioeng Biotechnol.
2021;9:636278.
50. Rasko DA, Sperandio V. Anti-virulence strategies for targeting bacterial pathogenesis. Nat Rev Drug Discov. 2010;9(2):117–28.
51. Hentzer M, Wu H, Falk R, Drenkard K, S. Molin, Givskov M, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J.
22003;22(14):3803–15.
52. Gomaa AA, Gomaa M. CRISPR-Cas technology in the fight against antibiotic resistance. J Antimicrob Chemother. 22019;74(12):3361–7.
53. Yang X, Chen J, Gong Z, Liu D, Ma X. CRISPR-Cas9 as a potential tool to combat antibiotic resistance. Future Microbiol. 22022;17:667–80.
54. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–83.
55. Ramaraj A, Sanjana SN, Kapoor N, Gupta R, Jainkuniya V, Gulati S. Antibiotic Prescription Patterns for Respiratory Infections in Urban Outpatient Settings in India: A Multicenter, Retrospective, EMR-Based Study Using WHO AWaRe Classification. Journal of the Epidemiology Foundation of India. 2025 Jun 30;3(2):137-44.
56. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving universal health coverage and meeting the threat of antimicrobial resistance: a global response to meet global goals. Lancet. 2016;387(10033):2149–50.
57. Abbo LM, Cosgrove SE, Srinivasan A, MacDougall C. Implementing Antimicrobial Stewardship Programs in Hospitals. Clin Infect Dis. 22014;58(8):1063–9.
58. Huijbers PM, Blaak H, de Jong MC, Graat EA, Vandenbroucke-Grauls CM, de Roda Husman AM. Role of the environment in the transmission of antimicrobial resistance to humans: a review. Environmental science & technology. 2015 Oct 20;49(20):11993-2004.

Ahead of Print Subscription Review Article
Volume 03
02
Received 27/01/2026
Accepted 29/04/2026
Published 01/07/2026
Publication Time 155 Days
1

Login


My IP

PlumX Metrics